NVCT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Nuvectis Pharma Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 21.52 USD
11.4% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 86.4% above the Trend Line and sits at 67.3% of its 52-week range. The latest completed week returned 11.4%, after a 10.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 48/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal; earnings are due in 1d.

Setup score 57 out of 100
Latest Close 21.52 USD 31 Jul 2026
1W Return 11.4% latest completed week
4W Return 10.0% short-term follow-through
12W Return 84.7% quarterly tape
Trend Breadth 55.8% 29 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 29-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 40.72% based on similar historical setup states.
  • 2 reversal markers appear in the recent smart-money tape.
  • The share remains more than 20% below its 52-week high.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 11.4% Latest completed week; four-week move 10.0%. Indicator stack 76/65 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.72% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 48/100 conviction; expected move 43.9%. News sentiment 59/100 59 relevant articles in the latest sentiment read. Event risk 1d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 86.4% above the Trend Line and sits at 67.3% of its 52-week range. The latest completed week returned 11.4%, after a 10.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8512-week average 0.74

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.85Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 10.0% over four weeks, 84.7% over 12 weeks, and 216.5% over one year. The current trend has remained active for 29 consecutive weeks.

Performance by holding period

1W11.4%
4W10.0%
12W84.7%
26W165.4%
52W216.5%
Active trend streak29 weeks
Active weeks in one year29
Trend breadth55.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.99Latest activity-pressure read.
Pressure change-32.7%Four-week change in activity pressure.
Leadership113.33Latest relative-leadership reading.
RS change10.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 61% Model confidence 57%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength48/100Blend of value, momentum, and quality. Underlying universe rank 53; rank 1 is best.
Value48/100Relative valuation strength. Underlying universe rank 53; rank 1 is best.
Quality46/100Profitability and accounting quality. Underlying universe rank 55; rank 1 is best.
Momentum49/100Medium-term price momentum. Underlying universe rank 52; rank 1 is best.
Growth48/100Revenue and earnings growth. Underlying universe rank 53; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-2.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-2.1%
Net share repurchases relative to market value.
Shareholder yield
-2.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

NVCT shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 10.19, expected move of 43.9%, and Sharemaestro trend signal active.

Conviction48/100
Expected move43.9%
Put/call volume10.19
Pressure-71
Speculation40
Volatility96
Trend agreement0
Open options detail
Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment59/100

Weighted news tone is neutral across 59 relevant articles.

25 positive · 30 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings1dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move43.9%Nearest-chain priced movement where available.
52-week drawdown-26.5%Distance below the 52-week high.
13-week volatility29.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2611 weeks finished lower.
Best week+96.7%Week of 26 Jun.
Worst week-28.0%Week of 3 Jul.
Latest week+11.4%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains4
Flat weeks1
Modest losses3
Sharp losses8
Recent vol29.5%13-week weekly-return volatility.
Base vol16.1%52-week weekly-return volatility.
Up/down split29/22Count of positive and negative weeks in the 52-week window.
Average skew10.1% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape55/100

Trend, activity pressure, participation, and risk combine to a 55/100 tape read.

 Indicator analysis85/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.85; 2 reversal markers Next-Week ExpectancyNegative 40.72%

Next-week expectancy is negative with a 40.72% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors47/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 79; Small Cap Core rank 55 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options34/100

NVCT shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 10.19, expected move of 43.9%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 43.9% Sentiment59/100

Weighted news tone is neutral across 59 relevant articles.

Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings1d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202621.52 USD11.4%11.55 USD8.56 USD0.99113.331.1MOn
24 Jul 202619.31 USD0.9%11.11 USD8.51 USD1.1597.381.3MOn
17 Jul 202619.14 USD4.3%10.73 USD8.48 USD1.4196.331.2MOn
10 Jul 202618.35 USD-6.2%10.35 USD8.45 USD1.6083.821.8MOn
3 Jul 202619.57 USD-28.0%9.99 USD8.43 USD1.47102.725.2MOn
26 Jun 202627.19 USD96.7%9.56 USD8.40 USD1.13189.784.0MOn
19 Jun 202613.82 USD29.0%8.86 USD8.33 USD0.7845.87713.7KOn
12 Jun 202610.71 USD12.3%8.60 USD8.35 USD0.6016.62337.5KOn
5 Jun 20269.54 USD-2.2%8.45 USD8.40 USD0.756.09355.8KOn
29 May 20269.75 USD-5.8%8.33 USD8.45 USD1.023.04418.0KOn
22 May 202610.35 USD-6.2%8.23 USD8.50 USD0.7711.71636.9KOn
15 May 202611.04 USD-5.2%8.10 USD8.55 USD0.4719.72717.8KOn
8 May 202611.65 USD36.4%7.93 USD8.58 USD0.0925.30706.6KOn
1 May 20268.54 USD-4.0%7.74 USD8.61 USD-0.35-3.40219.5KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.